Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011168 (dysphagia)
 15,644 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

(1) The failure of ;Slow-K' tablets to disintegrate prevents rapid release but allows them to be trapped by their bulk in the intestine.(2) Two cases are reported. In the first the tablet was trapped in a caecal diverticulum and the patient developed an abcess. In the second, abdominal pain developed which subsided when ;Slow-K' was stopped. Later ;Slow-K' was again started and the patient developed dysphagia.(3) The possibility of abdominal complications with this treatment should be remembered.(4) Effervescent KC1 preparations may replace ;Slow-K' but KC1 supplementation may be necessary only in cardiac disease.
J R Coll Gen Pract 1976 Aug
PMID:Complications of "slow-K" therapy. 96 9

Four patients with sporadic olivopontocerebellar atrophy (OPCA) and severe signs of Parkinsonism received continuous subcutaneous lisuride infusion via a small external pump. All 4 patients benefitted from this treatment: 3 showed an overall improvement in motor performance, in 1 patient mainly dysphagia and dysarthria improved. Therapeutic benefit lasted for at least 6 months of follow up. With a daily dose of 1.0 mg subcutaneous lisuride, treatment limitations were reached in the form of dysphagia, probably due to oropharyngeal dystonia. Subcutaneous lisuride infusion should be taken into consideration in OPCA patients with signs of Parkinsonism if oral dopaminergic treatment has failed earlier on.
J Neural Transm Gen Sect 1992
PMID:Continuous subcutaneous lisuride infusion in OPCA. 146 93

1. Neuroleptic drugs (antipsychotics) produce numerous side effects which include serious extrapyramidal symptoms consisting of akathisia, dystonia, neuroleptic malignant syndrome, parkinsonian reactions such as postural abnormality, tremor, akinesia or bradykinesia, rigidity, and tardive dyskinesia. 2. Among the complications of neuroleptic chemotherapy, the most serious and potentially fatal complication is malignant syndrome, which is characterized by extreme hyperthermia, "lead pipe" skeletal muscle rigidity causing dyspnea, dysphagia, and rhabdomyolysis, autonomic instability, fluctuating consciousness, leukocytosis, and elevated creatine phosphokinase. 3. Neuroleptic malignant syndrome should be differentiated from malignant hyperthermia, lethal catatonia, and other pathological states producing some of these same symptoms. 4. In addition to neuroleptics, malignant syndrome has been caused by thymoleptics (antidepressants), metoclopramide (antiemetic), metoclopramide combined with cimetidine, tetrabenazine, overdosage of benzodiazepine, phenelzine, dothiepin and alcohol, and amphetamine. 5. Factors leading to and/or facilitating the emergence of neuroleptic malignant syndromes are reportedly organic brain syndrome, dehydration, exhaustion, external heat load, excessive sympathetic discharge, use of long acting neuroleptics, high doses of neuroleptics, rapid dose titration with neuroleptics, abrupt discontinuation of antiparkinsonism agents, and concurrent lithium therapy. 6. Although, the pathogenesis of neuroleptic malignant syndrome is not understood completely, a blockade of dopaminergic receptors in the hypothalamus, spinal cord and striatum, an alteration of dopaminergic-serotonergic transmission in the body, an enhanced synthesis and action of prostaglandin E1 and E2, and a modification of calcium-mediated signal transduction in the body have been suggested. 7. The treatment of malignant syndrome includes immediate withdrawal of neuroleptic drugs, i.v. infusion of dantrolene, and oral administration of bromocriptine; or alternatively i.v. infusion of dantrolene and the combination of levodopa-carbidopa. 8. Other measures to enhance the therapeutic effectiveness of the aforementioned regimens are to include the use of anticholinergic drugs such as benztropine to enhance the effectiveness of bromocriptine, of lorazepam if catatonic symptoms persist, or of electroconvulsive therapy (ECT) if psychotic symptoms persist. 9. These treatments, however, must be "active" rather than "passive", in order to avert fatalities and/or unfortunate sequelae from this iatrogenic and incompletely understood disease.
Gen Pharmacol 1990
PMID:Pathogenesis and treatment of neuroleptic malignant syndrome. 197 19

Pharyngoesophageal dysphagia is chiefly a disorder of the elderly. This review examines recent advances in the understanding of the normal physiology of oropharyngeal bolus transport. Techniques for the evaluation of symptomatic patients are discussed with an emphasis on the complementary nature of manometry and videoradiography. The technical limitations of manometry are detailed. Therapy for the condition is aimed at the underlying cause, and patients with neurologic deficits (largest subgroup of patients) should have a good response to myotomy provided they fulfill basic criteria. Surgery for Zenker's diverticulum is always necessary, and a short discussion of technique has been included.
Curr Opin Gen Surg 1993
PMID:Pharyngoesophageal swallowing disorders. 758 64

A case of elongated stylohyoid ligament complex produced neck pain and dysphagia. The ossification of the stylohyoid complex and symptoms occurred after an automobile accident and were caused by cervicopharyngeal trauma. The patient was diagnosed with Eagle's syndrome based on clinical and radiographic examination. A stylohyoidectomy was performed, which led to the complete resolution of symptoms.
Gen Dent
PMID:Eagle's syndrome: a clinical report and review of the literature. 969 42

Globus hystericus, a form of conversion disorder, is characterized by an uncomfortable sensation of a mass in the esophagus or airway. Evaluation proves no mass exists. Anxiety or psychological conflict is judged to be significantly related to the onset and progression of the sensation. The sensation may lead to difficulty swallowing or breathing and may become severe or life threatening. The disorder is poorly studied and understood. The differential diagnosis is vast. Management of the disorder is similar to that suggested for other conversion disorders. This article reviews the current literature about diagnosis, etiology, treatment, and prognosis of globus hystericus.
Gen Hosp Psychiatry
PMID:Globus hystericus: a brief review. 1475 7

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction that causes muscle weakness and fatigue. Fluctuating fatigue of skeletal muscles is the key clinical feature. Late-onset MG is more frequent in elderly men and is often misdiagnosed. While involvement of oropharyngeal musculature has been described with symptoms of dysphagia and slurred speech, the presence of fluctuating dysphonia as the first symptom of late-onset MG has not been emphasized. The case of an elderly man, who demonstrated voice changes and later swallowing impairment with weight loss, is reported. This case presentation of late-onset MG emphasizes that this form of the disease should be considered in the differential diagnosis of acute onset dysphonia in elderly persons.
J Gen Intern Med 2006 Jun
PMID:Dysphonia as first symptom of late-onset myasthenia gravis. 1680 32

Chronic graft versus host disease (cGVHD) is the most common late complication of allogeneic bone marrow transplantation. The oral cavity is the most common site of cGVHD involvement. This study sought to investigate the incidence of oral cGVHD, as well as the disease's impact on a patient's quality of life and the kind of lesions that resulted. Nineteen patients with cGVHD received a medical and dental evaluation; 18 (94.7%) had oral lesions. Nine patients (47.3%) demonstrated xerostomia and 6 (35.2%) demonstrated dysphagia. Six patients (35.2%) had a lichenoid clinical form of cGVHD in the oral cavity, 6 (35.2%) had an atrophic-ulcerative clinical form, 3 (17.6%) had a hyperceratotic clinical form, and 2 (10.5%) had mixed forms. The results demonstrated predominance of lichenoid and ulcerative-atrophic forms with similar incidence of these lesions. No factor that could contribute to the severity of cGVHD oral lesions was found.
Gen Dent
PMID:Oral involvement in chronic graft versus host disease: a prospective study of 19 Brazilian patients. 1733 67

A 45-year-old man presented with dysphagia. Computed tomography and magnetic resonance imaging showed an abnormal shadow in the paraesophageal mediastinum, which a thoracoscopic biopsy revealed to be a desmoid tumor that had infiltrated the surrounding tissues. We attempted esophageal stent placement; however, the esophageal stenosis could not be dilated, and bypass surgery was performed first, with tumor resection postponed, and radiation and hormonal therapy were added. Mediastinum desmoid tumors are rare, with only 22 other cases reported in the English language literature. Herein, we report the details of our patient and provide a review of other cases.
Gen Thorac Cardiovasc Surg 2007 Mar
PMID:Paraesophageal mediastinal desmoid tumor: case report. 1744 11

Dysphagia is a common side effect of many systemic conditions that greatly affect oral care. This article draws from the literature concerning the pathophysiology, diagnosis, and treatment of dysphagia as it relates to dental care. Treatment of dysphagia requires a multidisciplinary approach. Dentists are integral to the management of dysphagic patients, which includes improving natural or artificial dentition to aid in mastication and function and stressing the importance of adequate oral hygiene.
Gen Dent
PMID:Dysphagia: pathophysiology, presentation, diagnosis, and dental management. 1981 16


1 2 3 Next >>